Uveitis Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Corticosteroids, Immunosuppressant, Monoclonal antibodies, Antibiotics, Antivirals, Antifungal, Analgesics), By Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis) By Cause (Infectious Uveitis, Non-Infectious Uveitis), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Others) and Region.     

Uveitis Treatment Market size was valued at US$ 697 million in 2023 and is poised to grow at a significant CAGR of 5.7% from 2024 to 2030. Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies.

Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate during the forecast period. Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn's disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.

Key Developments:

• On November 8, 2024: Santen Pharmaceutical and Arctic Vision have signed a commercial collaboration agreement for the ARVN001 suprachoroidal injectable suspension, a treatment for uveitic macular oedema (UME) and other ocular conditions. The agreement grants Santen exclusive commercialisation rights in China, excluding Hong Kong, Macau and Taiwan. Arctic Vision will obtain up to $85m in upfront and milestone payments. The partnership aims to combine the strengths of both companies to serve UME patients and expand in the Chinese ophthalmology market.
• On February 23, 2023: AbbVie and Capsida Biotherapeutics Inc. announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie’s extensive capabilities will be paired with Capsida’s novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021.